Genetic Testing
Screening Method for Lynch Syndrome in Endometrial and Ovarian Cancer
Recruiting1 award8 criteria
Toronto, Ontario
This trial will test a new way of identifying women with Lynch Syndrome, a hereditary disease that can lead to cancer. If successful, it could improve screening and surgery options for women at risk.
Monoclonal Antibodies
Combination Immunotherapy for Colorectal Cancer
Recruiting1 awardPhase 2
New York, New York
This trial is testing two special drugs that help the immune system fight a specific type of cancer. The drugs are given to see if they can shrink the cancer. The study focuses on patients who might not respond well to other treatments. The goal is to see if these drugs are safe and effective.
CAR T-cell Therapy
TC-510 Cell Therapy for Cancer
Recruiting1 awardPhase 1 & 2
Nashville, Tennessee
This trial tests TC-510, a therapy using a patient's own modified T cells to target and attack cancer cells. It is aimed at patients with cancers that are hard to treat with standard methods. The modified T cells are designed to recognize specific proteins on cancer cells and get an extra boost to kill them.
Popular Filters
Trials for Colorectal Cancer Patients
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
AH-HA EHR Tool for Heart Health in Cancer Survivors
Recruiting1 award6 criteria
Cedar Rapids, Iowa
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Trials for Colon Cancer Patients
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
AH-HA EHR Tool for Heart Health in Cancer Survivors
Recruiting1 award6 criteria
Cedar Rapids, Iowa
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Trials for Metastatic Patients
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
PARP Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Trials With No Placebo
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
AH-HA EHR Tool for Heart Health in Cancer Survivors
Recruiting1 award6 criteria
Cedar Rapids, Iowa
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.